anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is an acute, randomized, controlled, cross-over study designed to identify dietary biomarkers of milk and cheese intake and to asses metabolic effects after the ingestion of a non-fermented product (milk) and a fermented product (cheese) in healthy subjects.

Twelve healthy participants (six women, six men) in fasted state will consume three different foods in a randomized order on three different study days. Two days prior to each dietary intervention, the run-in period is initiated, during which participants have to follow a restricted diet. Participants will receive a standardised meal for the last dinner during run-in phase. The same meal will be served on the day of the dietary intervention for lunch and for dinner (period of controlled diet). Before and after ingestion of the test foods, blood samples and urine samples will be collected (up to 6 hours). Additionally, 24h-samples will be collected. Primary outcomes (metabolites) will be measured in blood serum and plasma collected at 6 different time points and in urine collected at 7 different time points. Transcriptomics analysis will be performed on whole blood samples collected at 4 time points while clinical chemistry parameters will be assessed in blood samples withdrawn at 6 different time points.
A method and compound for promoting growth and priming the immune system in both animals and humans are disclosed. The disclosed method utilizes a compound derived from one or more of a lipopolysaccharide, Lipid A, and fractions, derivatives, and cellular components thereof of gram-negative bacteria. The compound is combined with conventional feed, such as corn-soy feed, for administration to animals, such as poultry. Human application is possible, as well. Kinomic analysis of tissues collected from sacrificed birds fed the dietary mixture of the inventive compound and conventional feed suggests that the biomass causes an alteration of signaling in multiple growth-related pathways. These pathways include, but are not limited to, those associated with the vascular endothelial growth factor (VEGF), the mitogen-activated protein kinase (MARK or MAP kinase), Ak strain transforming (Akt), and the neurotrophic tropomyosin-related kinase (NTRK). Evidence supports the conclusion that this alteration represents the modulation of the various pathways.
All participants will undergo a single \[18\]F-PSMA-1007 PET/CT or PET/MRI scan. Intravenous bolus injection of 4 MBq/kg +/- 10% of \[18\]F-PSMA-1007, up to a maximum of 400 MBq.
The present invention provides compounds having antimalarial activity. More specifically, the present invention provides novel compounds that are analogues of pantyhose. The panthenol analogues of the present invention have a particularly low IC against the anemic phase and gametophytes of malaria parasites 50 . In addition, the panthenol analogues of the present invention are characterized by low hepatic metabolism. Accordingly, the panthenol analogues of the present invention are particularly suitable for use in the therapeutic and/or prophylactic treatment of protozoan infections in a human or animal subject in need thereof. The present invention also provides pharmaceutical formulations comprising the same, as well as the same and pharmaceutical compositions containing the sameTherapeutic and/or prophylactic use of the pharmaceutical preparation.
Parents in the eBook attention-control group will complete one interactive, multimedia and multicomponent program that contains information about good parenting principles and is administered digitally. It will take parents about 60 minutes to complete the eBook attention control.
Methods, systems, and devices for improving continuous glucose monitoring (“CGM”) are described herein. More particularly, the methods, systems, and devices describe applying layered machine learning models to generate predicted sensor glucose values. The system may use the predicted sensor glucose values to display a sensor glucose value to a user. The layered models may generate more reliable sensor glucose predictions across many scenarios, leading to a reduction of sensor glucose signal blanking. The methods, systems, and devices described herein further comprise applying a plurality of micro model to estimate sensor glucose values under outlier conditions. The system may prioritize the models that are trained for certain outlier conditions when the system detects those outlier condition based on the sensor data.
FIELD: organic chemistry, chemical technology, pharmacy. SUBSTANCE: invention relates to novel derivatives of thiazole of the formula (I)   wherein R 1  means group of formulas: (a)  , (b)  , (c)   and (d)   wherein R 2  means group of the formula (II)  ; R 3  means hydrogen atom, alkyl, cycloalkyl and so on; R 4  means alkyl, phenyl, heteroaryl; R 5  and R 6  each independently each of other means hydrogen atom, heteroaryl; R 7  and R 8  each independently each of other means hydrogen atom; or R 7  and R 8  in common with nitrogen atoms with which they are bound form 5-6-membered heterocycle; R 9  means hydrogen atom, alkyl, cycloalkyl; R 10  means phenyl, benzyl and so on; A means carbonyl or sulfonyl; B means hydrogen atom; each among a-m means 0 or positive number from 0 to 2 but not 0 when R 1  means -NH 2 ; b means number from 0 to 4; c, d, f, g, k, l and m each independently each of other means 0 or 1 and therefore each among c, f and g can't mean simultaneously 0 and owing to m doesn't mean 0 when f or g mean 1; i means 0; e means number from 0 to 3; h means number from 0 to 5; j means number from 0 to 2 and sum e, h and j = 2-7; and their pharmaceutically acceptable salts. Invention relates also to derivatives of thiazole of the formula (XXXI)   wherein   and a have values indicated above and wherein R 3  doesn't mean hydrogen atom or methyl when R 1  means group (e)  , (f)  . Invention relates also to method for preparing compound of the formula (I) by interaction of compound of the formula (XXXI) with amine of the formula (III)   given in description of invention. Invention relates also to pharmaceutical composition eliciting properties to inhibit binding adhesive proteins and containing compound of the formula (I) and therapeutically inert carrier. Invention provides preparing the new compound eliciting properties to inhibit binding adhesive protein. EFFECT: improved preparing method, valuable medicinal properties of compounds. 20 cl, 1 tbl, 176 ex
OBJECTIVE: In this study, we aimed to enhance the treatment protocols and help understand the harm caused by the accidental ingestion of magnetic beads by children.
METHODS: Data were collected from 72 children with multiple gastrointestinal perforations or gastrointestinal obstructions. The 72 pediatric patients were divided into a perforation and a non-perforation group. The data collected for the analysis included the gender, age, medical history, place of residence (rural or urban), and symptoms along with the educational background of the caregiver, the location and quantity of any foreign bodies discovered during the procedure, whether perforation was confirmed during the procedure, and the number of times magnetic beads had been accidentally ingested.
RESULTS: The accuracy rate of preoperative gastrointestinal perforation diagnosis via ultrasound was 71%, while that of the upright abdominal X-ray method was only 46%. In terms of symptoms, the risk of perforation was 13.844 and 12.703 times greater in pediatric patients who experienced vomiting and abdominal pain with vomiting and abdominal distension, respectively, compared to patients in an asymptomatic state. There were no statistical differences between the perforation and the non-perforation groups in terms of age, gender, medical history, and the number of magnetic beads ingested (P > 0.05); however, there were statistical differences in terms of white blood cell count (P = 0.048) and c-reactive protein levels (P = 0.033). A total of 56% of cases underwent a laparotomy along with perforation repair and 19% underwent gastroscopy along with laparotomy. All pediatric patients recovered without complications following surgery.
CONCLUSION: Abdominal ultrasonography and/or upright abdominal X-ray analyses should be carried out as soon as possible in case of suspicion of accidental ingestion of magnetic beads by children. In most cases, immediate surgical intervention is required. Given the serious consequences of ingesting this type of foreign body, it is essential to inform parents and/or caregivers about the importance of preventing young children from using such products.
In addition to standard care in the clinic, cold therapy will be applied to the children in the intervention group while they are receiving VCR in the inpatient pediatric oncology clinic. Children in the intervention group will wear cold therapy gloves and socks.To maintain the appropriate level of cold, the research assistant will replace the iced gel packs in the gloves and socks every 5 min during the treatment.
Migraine is a cyclic disorder marked by varying activity in different brain regions. It is generally believed that migraine involves a pronociceptive pain modulation pattern, likely due to impaired endogenous pain inhibitory systems. However, there are few studies in this respect, and different experimental approaches have produced mixed results, showing both normal and abnormal pain responses in migraine. Most research has focused only on episodic migraine (EM) during headache-free periods, leaving the role of pain modulation dysfunction in recurring migraines and the progression to chronic migraine unexplored. Conditioned Pain Modulation (CPM) tests, which measure the "pain inhibits pain" effect, are commonly used to assess inhibitory pain modulation. Studies comparing CPM responses in migraine sufferers and healthy individuals have yielded inconsistent findings, with some showing reduced inhibitory responses in migraineurs, while others found no difference. Offset Analgesia (OA) is another method used to study descending pain modulation systems in chronic pain conditions. Unlike CPM, OA examines temporal filtering of pain when dynamic noxious stimuli are applied and is characterized by a large reduction in pain sensation after a small decrease in a heat stimulus. Research indicates that central mechanisms, including the activation of descending pain modulatory and reward systems, play a significant role in OA. Only one study has explored the OA response in episodic migraine patients during headache-free intervals, finding no inhibitory pain modulation in the trigeminal area. This study aims to: 1) assess changes in pain modulation across the migraine cycle in EM patients, and 2) determine if different dysfunctional pain modulation patterns are present in chronic migraine, both with and without medication-overuse headache (CMwoMOH and CM-MOH).

Subjects and methods. The investigators will enroll 30 subjects with EM, 30 patients with CM (with and without MOH), and 30 healthy control subjects. Patients with EM during the preictal, ictal, and postictal phases will be also enrolled. All participants underwent an experimental paradigm consisting of three stimulus offset trials (OT) and three constant temperature trials (CT) applied to the forehead based on the individual heat pain threshold (HPT). All tests will be carried out by using a Q-sense CPM device (Medoc) and computerized visual analogue scale (CoVAS).

Experimental paradigms. All subjects will be assessed in a single experimental session. After obtaining written consent, participants will complete various questionnaires. The Heat Pain Threshold (HPT) will be then measured on the forehead (1st branch of the trigeminal nerve, V1), followed by three constant trials (CT) and three offset-analgesia trials (OT) in the same area. The following questionnaires will be administered: 12-item Allodynia Symptom Checklist (ASC-12), Migraine Disability Assessment (MIDAS), and Hospital Anxiety and Depression Scale (HADS).
There are approximately 100 new cases of spinal cord injuries (SCI) each year in Norway. Most of the SCI occur after traumatic accidents among young people and adults during the time of their productive life. Loss of walking and standing ability restricts their independent mobility and autonomy and severely impacts their quality of life.

The study has two arms: 1) manual locomotor training (Tromsø) and 2) robot assisted training (Oslo). Each study arm has 30 patients, randomized to receive standard care or intervention. The intervention group receives 60 days of intensive locomotor training over 6 months. Single-blind, before/after evaluation of effect will be performed at Sunnaas hospital using a standardized set of evaluation tools.
INTRODUCTION: The complex nature of Sjögren's Disease (SjD) necessitates a comprehensive and patient-centered approach in both diagnosis and management. This narrative review emphasizes the need for a holistic understanding of the connection between salivary gland inflammation and oral symptoms in SjD.
AREAS COVERED: The intricate relationship between salivary gland inflammation and dry mouth is explored, highlighting the variability in associations reported in studies. The association of the severity of xerostomia and degree of inflammation is also discussed. The frequent presence of recurrent sialadenitis in SjD further accentuates the connection of compromised salivary gland function and inflammation. The review additionally discusses local inflammatory factors assessed through salivary gland biopsies, which could potentially serve as predictors for lymphoma development in SjD. Insights into compromised quality of life and hypercoagulable state and their association with salivary gland inflammations are provided. Advancements in noninvasive imaging techniques, particularly salivary gland ultrasonography and color Doppler ultrasound, offer promising avenues for noninvasive assessment of inflammation.
EXPERT OPINION: There is a need for longitudinal studies to unravel the connections between salivary gland inflammation and oral symptoms. This will enhance management strategies and optimize treatment outcomes for SjD patients.
Study 247 was a randomized, double-blind trial (with open-label follow-up) conducted in HIV-infected patients with at least nine months of prior antiretroviral therapy and baseline CD4 cell counts less than or equal to 100 cells per μL. NORVIR 600 mg twice-daily or placebo was added to each patient's baseline antiretroviral therapy regimen, which could have consisted of up to two approved antiretroviral agents. The study accrued 1,090 patients, with mean baseline CD4 cell count at study entry of 32 cells per μL. After the clinical benefit of NORVIR therapy was demonstrated, all patients were eligible to switch to open-label NORVIR for the duration of the follow-up period. Median duration of double-blind therapy with NORVIR and placebo was 6 months. The median duration of follow-up through the end of the open-label phase was 13.5 months for patients randomized to NORVIR and 14 months for patients randomized to placebo.

The cumulative incidence of clinical disease progression or death during the double-blind phase of Study 247 was 26% for patients initially randomized to NORVIR compared to 42% for patients initially randomized to placebo. This difference in rates was statistically significant.

Cumulative mortality through the end of the open-label follow-up phase for patients enrolled in Study 247 was 18% (99/543) for patients initially randomized to NORVIR compared to 26% (142/547) for patients initially randomized to placebo. This difference in rates was statistically significant. However, since the analysis at the end of the open-label phase includes patients in the placebo arm who were switched from placebo to NORVIR therapy, the survival benefit of NORVIR cannot be precisely estimated. 

During the double-blind phase of Study 247, CD4 cell counts increases from baseline for patients randomized to NORVIR at Week 2 and Week 4 were observed. From Week 4 and through Week 24, mean CD4 cell counts for patients randomized to NORVIR appeared to plateau. In contrast, there was no apparent change in mean CD4 cell counts for patients randomized to placebo at any visit between baseline and Week 24 of the double-blind phase of Study 247.
The anesthetic methods are divided into the following 3 kinds: Sevoflurane, Propofol, Dexmedetomidine. These anesthetic drugs are used in general anesthesia generally.
Eating disorders can cause a decrease in athletic performance and affect the overall health of athletes. Athletes are exposed to an increased risk of developing pathological eating behaviors and dissatisfaction with their bodies. A number of studies have found higher rates of eating pathologies in aesthetic sports such as dance, ice skating, and gymnastics. Other studies have found that intervention programs designed to prevent eating disorders in athletes have yielded promising results. The current study will examine the effects of a controlled clinical intervention program designed to prevent eating disorders and improve the body image of female adolescent figure skaters and dancers. The program will consist of ten 45-minute interactive sessions led by the researcher. Each session will include a brief theoretical background, experiential activities (artistic or cognitive / emotional) and group discussions. The control group shall include age matched athletes who will not participate in the intervention program. The impact of the intervention shall be assessed with a nonrandomized, controlled experimental group design. To assess the impact and outcome of the intervention, all participants in the research and control groups will be asked to complete the study questionnaire at pre, post, and 3-month (after post) follow-up assessments. Process evaluation, which assesses program dissemination, attendance and relapse rates, as well as assessment of participants' satisfaction, will be performed at the end of the program. The study questionnaire includes: Personal and Demographic Information, EDI-2 (Eating Disorders Inventory), Body Esteem Scale-Mendelson, SATAQ-4 (Sociocultural Attitudes Towards Appearance Questionnaire-4), EDE-Q 8 (Eating Disorder Examination Questionnaire- 8), BAS (Body Appreciation Scale). All questionnaires have good psychometric properties. The study hypothesis is that the intervention program will result in improvement in the intervention group in terms of: disturbed eating behaviors, pursuit of thinness, body-dissatisfaction and external influences on body image compared with an age-matched control group that did not participate in the program.
<P>PROBLEM TO BE SOLVED: To provide orthopedic surgical instruments, and more particularly, systems, devices, and methods for determining and displaying joint force data.  <P>SOLUTION: A hand-held display module includes a housing, a display coupled to the housing, and a circuit positioned in the housing and coupled to the display. The circuit includes a receiver circuit configured to communicate with a sensor module positioned in a knee joint of a patient to receive joint force data indicative of the joint force of the patient's knee joint. In one mode, the circuit is configured to display a visual indication of the internal-external balance of the joint force based on the joint force data. In a second mode, the circuit is configured to display a visual indication of the internal-external and the anterior-posterior balance of the joint force.  <P>COPYRIGHT: (C)2011,JPO&INPIT
The invention belongs to the field of veterinary drugs, and specifically relates to a compound artemisinin multiphase lipidosome injection as well as a preparation method thereof. The injection comprises a medicinal component and an auxiliary material of the injection, wherein the medicinal component is prepared from artemisinin and diminazene aceturate, and the auxiliary material of the injection consists of lecithin, cholesterol, tween-80, a phosphate buffer and absolute ethyl alcohol. The injection comprises the following components in parts by weight: 1-30 parts of lecithin, 0.5-10 parts of cholesterol, 0.1-5 parts of tween-80, 0.5-5 parts of artemisinin, 0.5-5 parts of diminazene aceturate, 1-15 parts of absolute ethyl alcohol and 5-90 parts of the phosphate buffer. The compound artemisinin multiphase lipidosome injection prepared by the preparation method disclosed by the invention is remarkable in curative effect in treating eperythrozoonosis of livestock and poultry in clinical treatment of veterinarians, and is high in safety. Several methods are organically combined, i.e., an ethanol injection-ultrasonic treatment-homogenization method is adopted. The compound artemisinin multiphase lipidosome injection prepared by the method is high in encapsulation efficiency, good in stability, strong in operability and applicable to industrialized production on a large scale.
A method of treating COPD, asthma, pneumonia, bronchitis, cystic fibrosis, pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis and PAH in a patient. One embodiment includes the administration of a vasodilator prostacyclin analog, such as beraprost or iloprost, alone or in combination with a form of ethazine or zileuton. Other embodiments may include fluvoxamine. The vasodilator prostacyclin analogue is inhaled. The ethazine/zileuton is inhaled into the lungs or administered orally or intravenously. Other embodiments include fluvoxamine. This treatment reduces disease progression, reduces life threatening deterioration, and improves quality of life. The treatment is also useful for COPD patients with eosinophilia who are incompletely treated with steroids and addresses steroid-unresponsive disease components of COPD, including pulmonary hypertension and intravascular inflammation and bronchiectasis. Such treatments may include PDE4 inhibitors and current therapies employing existing steroids and beta-adrenergic receptor agonists and/or muscarinic receptor blockers. The treatment was also used for ARDS and COVID-19.
Family engagement in the ICU is recommended by critical care professional societies, but insufficient evidence of its benefits for patients and family members has hindered clinical uptake. Thus, high-quality evidence is needed to promote and support family engagement practices. A specific unmet need is to identify strategies to improve the recruitment and retention of families in clinical trials in the ICU setting. The objective of this study is to evaluate recruitment and retention strategies for clinical trials involving family members in the ICU setting.

Methodological Approach: We will use a Study Within a Trial (SWAT) design to embed a factorial randomized trial of 160 participants enrolled across our group's three ongoing studies involving family members of ICU patients: FAME, VR-Family, and NGAGE. We expect 160 participants to be enrolled over a 6-month period. Participants will be randomized by 2x2 factorial design to selected recruitment and/or retention strategies. The co-primary outcomes will be (1) recruitment rate and (2) retention rate.
The standard education and information booklet will be applied to both the experimental and control groups. Nurse navigation program will be applied to the experimental group. Within the navigation program, HPV DNA and Pap Smear Test Training and Counseling, Nurse Managed Telephone Support Line, Reminder Telephone Message, Transtheoretical Model and Motivational Interviews will be applied to individuals. Health Belief Model Scale for Cervical Cancer and Pap Smear Test: Psychometric testing is planned to be applied to both groups before and after the intervention in terms of outcome variables at 3 and 6 months.